Kirk Henne

irk Henne serves as Head of Development Sciences at Denali. In this role, he supports Drug Metabolism and Pharmacokinetics, Quantitative Pharmacology, Metabolomics and Proteomics, and Bioanalytical teams to advance Denali's biotherapeutic and small molecule portfolio.

Prior to joining Denali in 2016, Kirk was Director of Drug Metabolism and Pharmacokinetics and Project Team Lead at Assembly Biosciences. This role was preceded by a ten-year term at Amgen as Principal Scientist and Group Leader in Pharmacokinetics and Drug Metabolism. Before that, he began his industrial career at Pfizer. Kirk has contributed to successful candidate identification, IND-enabling, and early clinical development activities for more than 20 molecules representing multiple modalities across therapeutic areas including oncology, inflammation, immunology, metabolic disorders, virology, and neurodegenerative diseases.